Hana Acquires Inex Marqibo; New Development Focus Is Adult & Elderly ALL
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Hana Biosciences initially will develop Marqibo for use in acute lymphoblastic leukemia following acquisition of the sphingosomal vincristine formulation from Inex